Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition capable of treating alzheimer's disease

A technology for Alzheimer's disease and composition, which is applied in the field of pharmaceutical compositions capable of treating Alzheimer's disease, and can solve problems such as undiscovered

Inactive Publication Date: 2014-03-05
SHENYANG PHARMA UNIVERSITY
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no drug that can treat AD in this multiple links at home and abroad.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition capable of treating alzheimer's disease
  • Pharmaceutical composition capable of treating alzheimer's disease
  • Pharmaceutical composition capable of treating alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] The design of this embodiment is a pharmaceutical composition capable of treating Alzheimer's disease, which is composed of galantamine and chlorpheniramine. The compatibility ratio of galantamine and perchlorate is (0.5-4): (17.5-70).

[0012] 1.1 Mouse platform method to determine the effect and compatibility ratio of compound galantamine on Alzheimer's disease

[0013] Take healthy male Kunming mice, and then divide them into 21 groups, including 12 compound groups, 7 single groups, normal control group and model group, normal control group and model group, and the normal control group and model group are given equal volumes of distilled water. Feed galantamine 4, 2, 1, 0.5mg / kg, chlorpheniramine 70, 35, 17.5mg / kg, galantamine / chlorpheniramine 4 / 70, 4 / 35, 4 / 17.5, 2 / 70, 2 / 35, 2 / 17.5, 1 / 70, 1 / 35, 1 / 17.5, 0.5 / 70, 0.5 / 35, 0.5 / 17.5mg / kg, continuous administration for 7 days. 20 minutes after the last administration, except for the normal control group, which was intrap...

Embodiment 2

[0019] Screening of the optimal ratio of galantamine and chlorpheniramine.

[0020] 2.1 Mouse platform method to determine the best ratio

[0021] Experimental animals and methods are the same as 1.1.

[0022] Orthogonal experimental design and Q 50 Methods Dosage design was carried out and analysis of variance was used to analyze the experimental results. There was a synergistic effect between galantamine and chlorpheniramine (F50 method), the Q value greater than 1 means that the combined effect of the formula is greater than the sum of the single effects. The results showed that the optimal dose ratio of galantamine / chlorpheniramine was 2 / 35mg / kg, and the Q value was the largest Q=1.77.

[0023] 2.2 Determining the best ratio by mouse avoidance method

[0024] Experimental animals and methods are the same as 1.2.

[0025] Orthogonal experimental design and Q 50 Methods The dosage was designed and the experimental results were analyzed by analysis of variance. There was...

Embodiment 3

[0028] This example relates to the improving effect of compound galantamine on memory acquisition disorder, memory consolidation disorder and memory reproduction disorder. .

[0029] 3.1 Improvement effect of compound galantamine on scopolamine-induced memory impairment in mice (stepping method)

[0030] Take healthy male Kunming mice, and then divide them into 7 groups, namely normal control group, model group, compound galantamine (COG) 4 / 70, 2 / 35, 1 / 17.5 mg / kg group, and chlorpheniramine 35 mg / kg group and galantamine 2mg / kg group. Except the normal control group and the model group were given equal volumes of distilled water, the rest of the groups were given corresponding drugs for 7 consecutive days. 20 minutes after the last administration, except for the normal control group, which was intraperitoneally injected with normal saline, the rest of the groups were intraperitoneally injected with 5 mg / kg of scopolamine, and 10 minutes later, they performed platform traini...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses treatment effect of a compound medicine on alzheimer's disease. The compound medicine is composed of galanthamine and meclofenoxate in a combination and matching dosage proportion of (0.5-4):(17.5-70), preferable 2:35. Under the matching condition, galanthamine and meclofenoxate are combined to achieve obvious improving effect for memory acquisition disorder, memory consolidation disorder and memory representation disorder. Meanwhile, the compound medicine can achieve effects of preventing and treating the alzheimer's disease by delaying brain ageing, reducing amyloid deposition in brain, protecting cholinergic neuron and the like. Moreover, learning memory can be improved and the alzheimer's disease can be prevented and treated by combined use of galanthamine and meclofenoxate.

Description

technical field [0001] The invention relates to a pharmaceutical composition capable of preventing and treating Alzheimer's disease. More specifically, it relates to a pharmaceutical composition consisting of galantamine and perchlorate aldehyde. Background technique [0002] Alzheimer's disease (AD), also known as senile dementia, is a neurodegenerative disease that occurs in old age and is characterized by progressive dementia. Its main clinical manifestations are progressive cognitive dysfunction and memory decline, personality and behavior changes, decreased judgment, social impairment, loss of self-care ability, and eventually death. It is the fourth leading killer after cardiovascular disease, cancer and stroke , seriously endangering the health and quality of life of the elderly. The World Health Organization has defined AD as one of the five key diseases in the 21st century. Although the exact etiology of AD is not completely clear, the hypothesis of cholinergic n...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/55A61P25/28A61K31/216
Inventor 徐成徐静华周晓棉于杨唐桂毅李琳李蔷黄少艺
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com